Trial Profile

A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 17 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; BI 836858 (Primary) ; Cytarabine (Primary) ; Daunorubicin (Primary) ; Decitabine (Primary) ; Dubermatinib (Primary) ; Enasidenib (Primary) ; Entospletinib (Primary) ; Gilteritinib (Primary) ; Ivosidenib (Primary) ; Lomonitinib (Primary) ; Pevonedistat (Primary) ; Revumenib (Primary) ; Samalizumab (Primary) ; SRA 515 (Primary) ; Venetoclax (Primary)
Indications Acute myeloid leukaemia
Focus Biomarker; Therapeutic Use
Acronyms The Beat AML Trial

12 Jun 2025 According to Syndax Pharmaceuticals Media Release, data from this trial presented in an oral session at the 30th European Hematology Association (EHA) Annual Congress Meeting
12 Jun 2025 According to Syndax Pharmaceuticals Media Release, data from this trial were published in the Journal of Clinical Oncology
12 Jun 2025 Results presented in the Syndax Pharmaceuticals Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com